Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Emergence of daptomycin-non-susceptible enterococci urinary tract isolates.

Kelesidis T, Humphries R, Chow AL, Tsiodras S, Uslan DZ.

J Med Microbiol. 2013 Jul;62(Pt 7):1103-5. doi: 10.1099/jmm.0.056630-0. Epub 2013 Apr 18. No abstract available.

PMID:
23598376
2.

Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections.

Fisher L, North D.

Int J Antimicrob Agents. 2009 May;33(5):493-4. doi: 10.1016/j.ijantimicag.2008.11.003. Epub 2009 Jan 18. No abstract available.

PMID:
19153034
3.

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

Kelesidis T, Humphries R, Uslan DZ, Pegues DA.

Clin Infect Dis. 2011 Jan 15;52(2):228-34. doi: 10.1093/cid/ciq113.

PMID:
21288849
4.

Daptomycin: A viable therapeutic option for vancomycin-resistant enterococcal urinary-tract infections in Indian medical settings?

Mohan B, Garg S, Appannanavar SB, Taneja N.

Indian J Med Microbiol. 2016 Jul-Sep;34(3):398-9. doi: 10.4103/0255-0857.188377. No abstract available.

5.

Study of virulence factors in association with antimicrobial resistance amongst urinary isolates of enterococci.

Tiwari K, Banerjee T, Filgona J, Anupurba S.

Indian J Med Microbiol. 2015 Jul-Sep;33(3):455-6. doi: 10.4103/0255-0857.158602. No abstract available.

6.

Proximity to animal or crop operations may be associated with de novo daptomycin-non-susceptible Enterococcus infection.

Kelesidis T, Chow AL.

Epidemiol Infect. 2014 Jan;142(1):221-4. doi: 10.1017/S0950268813000885. Epub 2013 Apr 15.

PMID:
23587411
7.

The zoonotic potential of daptomycin non-susceptible enterococci.

Kelesidis T.

Zoonoses Public Health. 2015 Feb;62(1):1-6. doi: 10.1111/zph.12091. Epub 2013 Nov 26. Review.

8.

Use of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series.

Ramaswamy DP, Amodio-Groton M, Scholand SJ.

BMC Urol. 2013 Jul 16;13:33. doi: 10.1186/1471-2490-13-33.

9.

In vitro activity of vancomycin and daptomycin against clinical isolates of Staphylococcus aureus and enterococci from India.

Jain S, Gaind R, Chugh TD.

Int J Antimicrob Agents. 2013 Jul;42(1):94-5. doi: 10.1016/j.ijantimicag.2013.02.025. Epub 2013 Apr 20. No abstract available.

PMID:
23611307
10.

In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: first results from Turkey.

Arslan H, Azap OK, Ergin F, Karaman SO, Oruç E.

Int J Antimicrob Agents. 2004 Jun;23(6):642-3. No abstract available.

PMID:
15194140
11.
12.

Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.

Lewis JS 2nd, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH.

Antimicrob Agents Chemother. 2005 Apr;49(4):1664-5. No abstract available. Erratum in: Antimicrob Agents Chemother. 2005 May;49(5):2152.

13.

De novo daptomycin-nonsusceptible enterococcal infections.

Kelesidis T, Humphries R, Uslan DZ, Pegues D.

Emerg Infect Dis. 2012 Apr;18(4):674-6. doi: 10.3201/eid1804.110932.

14.

Vancomycin-resistant enterococci.

Moellering RC Jr.

Clin Infect Dis. 1998 May;26(5):1196-9. Review.

PMID:
9597252
15.

In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin.

Entenza JM, Giddey M, Vouillamoz J, Moreillon P.

Int J Antimicrob Agents. 2010 May;35(5):451-6. doi: 10.1016/j.ijantimicag.2009.12.022. Epub 2010 Feb 24.

PMID:
20185277
16.

Characterization of daptomycin non-susceptible Enterococcus faecium producing urinary tract infection in a renal transplant recipient.

Sorlózano A, Panesso D, Navarro-Marí JM, Arias CA, Gutiérrez-Fernández J.

Rev Esp Quimioter. 2015 Aug;28(4):207-9.

17.

Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.

Johnson AP, Mushtaq S, Warner M, Livermore DM.

Int J Antimicrob Agents. 2004 Oct;24(4):315-9.

PMID:
15380254
18.

Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents.

Descourouez JL, Jorgenson MR, Wergin JE, Rose WE.

Antimicrob Agents Chemother. 2013 Mar;57(3):1518-20. doi: 10.1128/AAC.02099-12. Epub 2012 Dec 21.

19.

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).

Sader HS, Jones RN.

Diagn Microbiol Infect Dis. 2009 Oct;65(2):158-62. doi: 10.1016/j.diagmicrobio.2009.06.016.

PMID:
19748426
20.

Emergence of Enterococcus as a significant pathogen.

Moellering RC Jr.

Clin Infect Dis. 1992 Jun;14(6):1173-6. Review. No abstract available.

PMID:
1623072

Supplemental Content

Support Center